Goodsurance

Drug prices & Part D

With Open Enrollment Weeks Away, Medicare Rights Center Recaps What the Inflation Reduction Act Has Delivered for Part D in 2026

An August 27 analysis from the Medicare Rights Center outlines the drug law's current protections, including a first-ever Part D out-of-pocket cap and ten negotiated drug prices that took effect in January.

By the Goodsurance editorial teamAugust 30, 2026

With the 2027 Medicare Annual Enrollment Period less than seven weeks away, the Medicare Rights Center published an analysis on August 27 recapping the Inflation Reduction Act of 2022's changes to Part D prescription drug coverage and their current impact for beneficiaries.

Before the law's passage, Medicare Part D had no hard annual limit on what a beneficiary could owe out of pocket for covered drugs. Starting in 2025, the IRA established a cap, and the Medicare Rights Center notes that for 2026 that cap stands at 2,100 dollars, aligning Part D's protection with the limits long available in Medicare Advantage drug plans.

Ten Medicare-negotiated drug prices are now in effect for 2026. Here is what the 2022 drug law means for Part D enrollees heading into open enrollment.

Ten drugs selected in the law's first round of Medicare price negotiation entered the market at their negotiated prices on January 1, 2026. The medicines treat conditions including blood clots, diabetes, heart failure, autoimmune disorders, and certain cancers. CMS projected the negotiated prices would reduce what Part D enrollees pay out of pocket by 1.5 billion dollars annually and reduce Medicare's own drug spending by 6 billion dollars per year.

The analysis also notes that a third cycle of negotiations is now under way, covering fifteen additional drugs, with final prices expected later this fall.

The Medicare Rights Center highlighted open enrollment as the moment when beneficiaries should review their plan's drug formulary, verify their specific medications are covered at the lowest available cost-sharing tier, and confirm the plan passes through negotiated savings at the point of sale.

In plain words

The Medicare Rights Center explained what the 2022 drug law has done for people with Medicare Part D in 2026. There is now a limit on how much people pay for drugs in a year. In 2026, that limit is 2,100 dollars. Ten drugs that Medicare negotiated also cost less starting in January. A third round of negotiations is underway for fifteen more drugs. Open enrollment starts October 15. That is the time to check whether your drug plan still covers your medicines at the best price.

Source: Medicare Rights Center
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

CMS Proposes PBM Transparency Rules and Provider Directory Accuracy Standards for Medicare in 2028

A proposed rule published October 16 would require pharmacy benefit managers in Part D to disclose earnings and manufacturer deals to Medicare, require Medicare Advantage plans to publicly score their own provider directories, and cut generic drug copays to zero for the lowest-income dual-eligible enrollees.

October 17, 2026

Drug prices & Part D

Over 2 Million Enrollees in AARP-Branded Medicare Drug Plans Could Pay at Least 50 Dollars More Per Month in 2027 If They Do Not Switch

A KFF analysis found that AARP Medicare Rx Preferred monthly premiums are rising by at least 50 dollars in every state for 2027, with increases topping 100 dollars per month in four states, a separate finding from the same report that flagged the disappearance of zero-premium plans and one that lands two days before open enrollment opens October 15.

October 13, 2026

Drug prices & Part D

OIG: Medicare Part D Paid 587.7 Million Dollars for Drugs That Had Already Gone Over the Counter

A federal audit found that outdated FDA data in Medicare's prescription reference file allowed Part D sponsors to keep paying pharmacies for five drugs that had already switched to over-the-counter status between 2021 and 2023.

October 12, 2026

Drug prices & Part D

Medicare's GLP-1 Bridge Offers a 50-Dollar Monthly Pathway to Weight-Loss Drugs Through 2027

A CMS demonstration program launched in July gives eligible Part D enrollees access to Wegovy, Zepbound KwikPen, and Foundayo at a flat 50-dollar monthly copay, with no standard Part D deductible, through December 2027, after CMS said a planned longer-term coverage model will not launch in Part D in 2027.

October 11, 2026

Drug prices & Part D

PhRMA Files Federal Lawsuit to Block Medicare's New International Drug Pricing Model

The pharmaceutical industry's main trade group sued the Trump administration on October 7, arguing that a new rule tying Medicare Part B drug payments to prices in other countries exceeds the government's legal authority.

October 7, 2026

Drug prices & Part D

Federal Watchdog: Medicare Drug Plans Tied to Pharmacy Chains Offer Lower Premiums but Substantially Higher Drug Costs

With open enrollment eight days away, a federal audit found that Part D plans run by companies that also own pharmacies and pharmacy benefit managers dominate the market, but their enrollees pay substantially more out of pocket when filling prescriptions.

October 7, 2026